- Home
- RPAY vs SLP Comparison
RPAY vs SLP Comparison
Compare RPAY & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPAY | SLP |
|---|---|---|
| Founded | 2006 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | EDP Services |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.0M | 248.8M |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RPAY | SLP |
|---|---|---|
| Price | $2.72 | $12.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $6.03 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 1.4M | 253.8K |
| Earning Date | 06-09-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $309,261,000.00 | $59,577,000.00 |
| Revenue This Year | $8.67 | $2.64 |
| Revenue Next Year | $6.08 | $6.01 |
| P/E Ratio | ★ N/A | $411.00 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $2.69 | $11.16 |
| 52 Week High | $5.98 | $36.43 |
Technical Indicators
Market Signals| Indicator | RPAY | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 35.21 | 40.17 |
| Support Level | N/A | $12.45 |
| Resistance Level | $3.87 | $13.84 |
| Average True Range (ATR) | 0.19 | 0.51 |
| MACD | -0.01 | 0.29 |
| Stochastic Oscillator | 8.06 | 83.27 |
Price Performance
Historical ComparisonAbout RPAY Repay Holdings Corporation
Repay Holdings Corp is engaged in providing integrated payment processing solutions to verticals that have transaction processing needs. It allows customers to pay through Mobile App, Text, Interactive Voice Response, Virtual Terminal, Hosted Payment Page and Online Customer Portal among others. It operates in two segments Consumer Payments and Business Payments.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.